Gain Therapeutics Presents Phase 1b GT-02287 Data At International Congress Of Parkinson's Disease And Movement Disorders, Highlighting Safety, Tolerability, And Exploratory Findings In PD Patients With or Without GBA1 Mutation

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants

Plasma exposures in patients within projected therapeutic range and comparable to exposures observed in Phase 1 healthy volunteer study

GT-02287 was generally well-tolerated with no treatment emergent serious adverse events (TESAEs); no changes recommended from two independent DMC reviews

Gain to host GT-02287 KOL event on October 14th at 4 p.m. EST

BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today presented a poster at the International Congress of Parkinson's Disease and Movement Disorders® summarizing early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease (PD) with or without a GBA1 mutation.